Decoding the future: How ARTIFICIAL INTELLIGENCE (AI) is revolutionizing drug discovery

Anjali Salunke[1], Srushti Ganbote[2]
[1,2]ASPM'S K.T.Patil college of pharmacy, Dharashiv. 413501

***Abstract*—The process of drug discovery is inherently complex, time-consuming, and expensive, with a significant rate of failures along the way. However, the integration of artificial intelligence (AI) has notably transformed this field, allowing for quicker and more efficient identification and development of potential therapies. AI methodologies, such as machine learning, deep learning, and natural language processing, are increasingly utilized throughout various phases of drug discovery, including target identification, hit generation, and lead optimization. These techniques enhance the analysis of extensive biological and chemical datasets, thereby improving decision-making and lowering experimental expenses. Furthermore, AI is crucial for drug repurposing and optimizing the design of clinical trials by enhancing patient stratification. Despite these advancements, challenges related to data quality, model interpretability, and regulatory approval continue to be significant concerns. This review sheds light on the latest developments in AI-driven drug discovery, examines current limitations, and presents future outlooks for the integration of AI with traditional pharmaceutical research to expedite the development of safe and effective medications.**

***Index Terms*—Artificial intelligence, Machine learning, Target identification, drug discovery, AI-limitations.**

I. INTRODUCTION

Artificial Intelligence (AI) encompasses a vast area of computer science aimed at developing machines that can undertake tasks usually requiring human intelligence. Such tasks involve reasoning, learning, perception, understanding natural language, solving problems, and making decisions. AI systems leverage algorithms, data, and computing power to mimic certain aspects of human thought processes.(4)

The traditional drug discovery process is a highly intricate and demanding journey, often taking up to 15 years and costing between $1 to $2 billion for each drug that gains approval. This complexity stems largely from increasing attrition rates and prolonged clinical trial durations. Despite substantial investments, nearly 90% of potential drug candidates do not succeed, even after reaching the phase-I clinical trial stage. Successfully advancing a drug candidate to phase-I trials, following thorough optimization during the preclinical stage, is regarded as a major achievement for both pharmaceutical companies and academic institutions.(6)

The difficulties we've encountered underscore the pressing necessity for creative strategies to enhance and expedite the effectiveness of drug discovery.(6)

The advancement of computational capabilities and the introduction of new methodologies in AI have the potential to transform the drug discovery and development landscape. By utilizing AI, we can tackle the lengthy and expensive medication development process, which often suffers due to a lack of cutting-edge technology. AI excels at identifying promising compounds, accelerating the validation of drug targets, and refining the design of drug structures.(1)

Recent advancements in processing hardware and innovative deep learning (DL) algorithms have significantly enhanced the effectiveness of artificial intelligence (AI) across various fields, including computer vision, autonomous vehicles, robotics, and more.

AI models, which include machine learning (ML) and deep learning (DL), can analyse patterns and insights in the input data provided to them. From this analysis, they are able to categorize data (classification), predict numerical outcomes (regression), group similar data (clustering), and either create entirely new data or produce data that resembles the inputata.(5)

II. ROLE OF AI IN DRUG DISCOVERY

1. Machine Learning

Machine learning (ML) techniques have become essential in contemporary drug discovery owing to their capability to analyse intricate and high-dimensional biological data. ML algorithms capitalize on existing datasets to recognize patterns and foresee outcomes related to new data. Supervised learning methods, including support vector machines (SVMs) and random forests, are frequently utilized to predict drug-target interactions, toxicity profiles, and pharmacokinetic properties (ADMET).

2. Quantum computing(QC)

Quantum computing (QC) signifies a groundbreaking change in computational capabilities by harnessing principles of quantum mechanics like superposition and entanglement. This allows it to execute specific calculations at speeds that can be exponentially faster than those achievable by classical computers.

3.Natural Language processing

Natural Language Processing (NLP) techniques are progressively vital for deriving significant insights from the extensive unstructured biomedical literature, patents, and clinical trial reports.(2)

4. Deep Learning Models

Deep learning models mark a significant advancement in neural networks, enabling them to effectively analyse intricate biomolecular data. The key models include:

A. CNN: utilized for visual or structural representations.

B. RNN: capable of generating molecules based on their representations.

C. Transformers: inspired by natural language processing, these models are instrumental in representing molecule.(8)

5. Unsupervised Learning

These techniques come into play when data is either nonexistent or undefined, allowing the algorithm to identify patterns, groupings, or hidden structures. Their applications include:

A. “K-means” and “clustering” for assessing molecular clusters and identifying disease subtypes.

B. Principal Component Analysis (PCA) for reducing the dimensionality of compounds and visualizing the chemical landscape.

C. Self-Organizing Maps (SOM) for projecting extensive molecular datasets onto 2D maps. These methods are crucial for comprehending the chemical diversity of molecules and uncovering unknown relationships between various compound (8)



Fig: overview of AI and it’s key components.

III. APPLICATIONS OF AI IN DRUG DISCOVERY

1.Identifying and Validating Targets

AI plays a crucial role in enhancing drug target prediction through the analysis of various biological datasets. By integrating information from genomics, proteomics, and more, AI algorithms can uncover new targets with greater efficiency than traditional methods.

2.Screening Drugs and Discovering Leads

The advent of AI-powered virtual screening and in silico methods has transformed the way potential lead compounds are identified in drug discovery. These computational techniques allow for the rapid evaluation of extensive chemical libraries, significantly speeding up the process while lowering costs compared to conventional high-throughput screening.

3.Designing and Optimizing Drugs

AI-driven methodologies are changing the landscape of drug development by optimizing essential attributes like solubility, stability, and bioavailability.

4.Preclinical and Clinical Development

Effective drug development relies on predictive modelling of pharmacokinetics (PK), pharmacodynamics (PD), and toxicity profiles. AI techniques, especially machine learning, have made significant strides in enhancing these capabilities .(1)



Fig: Applications of AI in drug discovery.

IV. ADVANTAGES OF AI IN DRUG DISCOVERY

1.Time and Cost Efficiency

AI drastically cuts down the drug discovery timeline by automating processes like data analysis, virtual screening, and lead optimization.

2.Enhanced Target Identif extensive biological datasets, AI helps identify and validate new drug targets with greater precision.

3.Boosted Hit and Lead Discovery

AI-powered virtual screening allows for the quick evaluation of millions of compounds, leading to higher hit rates and the discovery of novel chemical scaffolds.

4.Increased Clinical Trial Efficiency

AI enhances clinical trial design through improved patient selection, stratification, and predictions of trial outcomes.

5.Personalized and Precision Medicine

AI facilitates personalized drug discovery by pinpointing patient-specific targets and forecasting individual treatment responses.(7)

6. Enhanced Prediction of ADMET Properties

Machine learning models can effectively forecast absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiles in the early stages of drug development. By predicting toxicity early on, the number of late-stage failures is minimized, ultimately enhancing the safety of new medications.

7. Drug Repurposing

AI streamlines the process of drug repurposing by uncovering new therapeutic uses for existing medications through the analysis of biological, chemical, and clinical data. This method lowers the risks associated with development and facilitates swifter entry into clinical trials.

8. Data Integration and Decision Support

AI brings together various data sources, including genomics, proteomics, chemical libraries, and real-world evidence. This comprehensive analysis aids in making informed decisions and helps diminish human bias.(7)

V. DISADVANTAGES OF AI IN DRUG DISCOVERY

1.High Implementation Costs: Setting up and maintaining AI systems involves significant investment in cutting-edge hardware, software, and ongoing support, making it a costly endover.

2.Lack of Originality: AI depends heavily on existing data and prior experiences, which restricts its ability to engage in creative or innovative problem-solving.

3.Potential for Unemployment: The rise of automation and AI-driven robotics has the potential to replace human jobs in certain sectors, leading to concerns over workforce reductions.

4.Emotionless Decision-Making: AI systems lack emotional intelligence and the ability to understand interpersonal dynamics , which are essential in collaborative research settings, thus limiting their capacity to fully substitute for human interaction.

5.Cognitive Dependence: Relying too much on AI for routine or repetitive tasks may diminish human involvement in problem-solving and memory retention, which could lead to a decline in cognitive engagement in future generations.(9)

VI. LIMITATIONS OF AI IN DRUG DISCOVERY

AI encounters considerable data challenges, including the scale, rapid growth, diversity, and uncertainty of data. Pharmaceutical companies dealing with drug development often have access to extensive data sets that can include millions of compounds. Traditional machine learning tools may struggle to effectively process such data. Additionally, QSAR-based models encounter issues such as limited training sets, experimental data inaccuracies in those sets, and insufficient experimental validation.

VII. HOW CAN WE ADDRESS THESE LIMITATIONS?

To tackle these challenges, recently developed AI techniques such as deep learning (DL) and related modeling studies can be utilized for evaluating the safety and efficacy of drug molecules through big data modeling and analysis. In 2012, Merck sponsored a QSAR machine learning challenge to highlight the benefits of DL in the drug discovery process within the pharmaceutical industry. The results demonstrated that DL models significantly outperformed traditional machine learning methods when predicting outcomes for 15 datasets related to absorption, distribution, metabolism, excretion, and toxicity (ADMET) of drug candidates.(3)

VIII. FUTURE DIRECTION

The pharmaceutical industry is currently grappling with rising costs and declining efficiency in the process of developing new drugs. However, the advent of advanced computational techniques has revolutionized traditional methodologies in drug development and discovery. Major pharmaceutical companies are increasingly adopting these cutting-edge technologies to create personalized treatments. By factoring in patient-specific details like age, weight, genetic makeup, and health status, AI algorithms can refine medication formulations and delivery systems, ultimately leading to improved treatment outcomes. Additionally, AI systems are set to change thelandscape of safety evaluations by predicting toxicity and potential side effects of drug candidates. As a result, screening expenses could be reduced by as much as 90%, excluding anticipated operational costs related to the implementation of adaptive learning processes.(4)



Fig: Applications of AI in real life.

IX. CONCLUSSION

- Revolutionising efficiency: AI drastically reduces drug discovery timelines and experimental expenses by automating data analysis and virtual screening. It has the potential to reduce screening costs by as much as 90%.
- Enhanced Precision and Safety: Advanced methodologies like machine learning and deep learning improve the identification of drug targets and the prediction of safety profiles (ADMET) early in the process, which minimizes late-stage clinical trial failures.
- Shift Toward Personalized Medicine: Future directions emphasize using AI to create personalized treatments tailored to individual factors such as genetics, age, and health status, leading to significantly improved patient outcomes.
- Overcoming Technical Limitations: While traditional tools struggle with the massive scale and diversity of pharmaceutical data, newer deep learning algorithms are proving effective at processing these complex datasets to evaluate drug safety and efficacy.
- Strategic Integration: The ultimate goal is the seamless integration of AI with traditional pharmaceutical research to expedite the delivery of safe, effective, and innovative medications.

REFERENCES

[1] Shashi Kant, Deepika, Saheli Roy, (2025) Artifcial intelligence in drug discovery and development:Transforming challenges into opportunities.
[2] Ajmal Rashid Bhat, Sumeer Ahmed, (2025) Artificial intelligence (AI) in drug design and discovery: A Comprehensive review.
[3] Debleena Paulz, Gaurav Sanapz, Snehal Shenoyz, Dnyaneshwar Kalyane, Kiran Kalia and Rakesh K. Tekade. Volume 26, Number 1 January 2021. Artificial intelligence in drug Discovery and development.
[4] Ishar K Thak, Pooja R. Hatwar, Ravindra L. Bakal, Om N. Ajmire and Gaurav P. Aswar.(2025) Artificial Intelligence used in Drug Discovery.
[5] Roohallah Alizadehsani, Solomon sunday oyelere, Sadiq Hussain, Senthil kumar Jagatheesaperumal, rene Ripardo Calixto, Mohamed Rahouti, Mohamad Roshanzami and Victor Hugo c. De Albuquerque.Explainable Artificial Intelligence for Drug Discovery and Development – A Comprehensive Survey.
[6] Ashfaq Ur Rehmana, Mingyu Li, Binjian Wu, Yasir Ali, Salman Rasheedd, Sana Shaheene, Xinyi Liua, Ray Luo, Jian Zhanga. (2025) Role of artificial intelligence in revolutionizing drug discovery.
[7] Yogesh Kakrambe, Dr. Kardile Prabhakar, Rajkumar Shete, Sambodhi Patil, Sandip pawar.(2026) Artificial Intelligence (AI) In Drug Discovery.
[8] Ana Beatriz Lopes, Célia Fortuna Rodrigues, Francisco A. M. Silva.(2026) From Algorithm to Medicine: AI in the Discovery and Development of New Drugs.
[9] Vaibhav Adhao, Kalyani Malthane, Jaya Ambhore, Rohini Jangle, Raju Thenge and Pavan Chinchole.(2026) A Comprehensive Review on Artificial Intelligence in Drug Discovery.
[10] Tejesvi Alekh Prasad.(2021) Real-World Applications of Artificial Intelligence.